Citation:Qi WX, Tang LN, He AN, Shen Z, Yao Y 2012

From Cancer Guidelines Wiki

Citation


Qi WX, Tang LN, He AN, Shen Z, Yao Y. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2012 Jan 19 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22258853.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Qi WX, Tang LN, He AN, Shen Z, Yao Y 2012What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Qi WX, Tang LN, He AN, Shen Z, Yao Y 2012 2Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Qi WX, Tang LN, He AN, Shen Z, Yao Y 2012 3Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Qi WX, Tang LN, He AN, Shen Z, Yao Y 2012 4What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Qi_WX,_Tang_LN,_He_AN,_Shen_Z,_Yao_Y_2012&oldid=21657"